Why the study?
DOACs are non-inferior to vitamin K antagonists for stroke prevention in non-valvular AF, but real-world Australian data were limited.
What are the real-world safety and efficacy outcomes, and predictors of bleeding and stroke, in patients taking DOACs for non-valvular atrial fibrillation?
Population
658 patients with non-valvular AF at a tertiary hospital in Victoria, Australia
Comparison
Real-world DOAC use, including low-dose vs full-dose DOAC
Design
Retrospective single-centre observational study
Authors
Loading...
Low-dose DOACs may increase bleeding in real-world AF; leaves open causal effects on stroke and optimal dosing strategies.
What are the real-world safety and efficacy outcomes, and predictors of bleeding and stroke, in patients taking DOACs for non-valvular atrial fibrillation?
In real-world practice, low-dose DOACs and high falls risk are paradoxically associated with both increased bleeding and thrombotic stroke risk in patients with non-valvular AF.
Brook et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: